Zobrazeno 1 - 10
of 21
pro vyhledávání: '"35"'
Publikováno v:
Leukemialymphoma. 33(1-2)
We report a retrospective survey of 35 patients (18 males and 17 females) with B-Prolymphocytic leukemia (B-PLL) followed for a median of 63 months. Twelve patients fulfilled Galton's original clinical and hematological criteria, presented with promi
Autor:
H. Jardel, S. Le Tortorec, Anne-Sophie Moreau, Claude-Eric Bulabois, Noel-Jean Milpied, J-L Harousseau, Marc-André Mahé, H Maisoneuve, Béatrice Mahé, M. J. Rapp, Philippe Moreau, Mohamed Hamidou, Benoit Dupas, Sylvain Bourdin, Nadine Morineau
Publikováno v:
Leukemialymphoma. 30(3-4)
Thirty-five adult patients with high-risk HD (HD) defined by (1) Ann Arbor stage IV or bulky nodal disease (tumor/thorax ratio > 0.45) and (2) no or partial response (PR) (< 75%) to the initial 3 courses of ABVD, received an early intensive therapy w
Autor:
Gunnar Juliusson, Ulla Frödin, Gerd Bäckström, Agneta Seger Mollén, Peter Söderkvist, Claes Malm, Karin Karlsson
Publikováno v:
Leukemialymphoma. 44(4)
The role of mixed chimerism on subsequent relapse was prospectively evaluated in an allotransplant program. Sixty-six patients with median age of 54 and mainly high-risk hematologic disease and/or solid tumors had individually adjusted non-myeloablat
Autor:
Richard R. Furman, John P. Leonard, Jia Ruan, Morton Coleman, Brian K. Link, Jonathan Reiss, Peter Martin
Publikováno v:
Leukemialymphoma. 56(10)
Existing data suggest that myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) peak in incidence 5-10 years following exposure to ionizing radiation, while most publications report less than 5 years of follow-up after radioimmunotherapy (
Autor:
Ryan D. Cassaday, Andrei R. Shustov, Mary Philip, David G. Maloney, Brian G. Till, William I. Bensinger, Colin Phipps, Barry E. Storer, Edward N. Libby, Leona Holmberg, Thomas R. Chauncey, John M. Pagel, Oliver W. Press, Damian J. Green, Maria Corinna Palanca-Wessels, Ajay K. Gopal
Publikováno v:
Leukemialymphoma. 56(1)
Patients with rituximab-refractory follicular lymphoma (FL) have limited options. Before the rituximab era, autologous stem cell transplant (ASCT) was shown to improve outcomes in chemotherapy-sensitive, relapsed FL, but the impact of rituximab-sensi
Autor:
John F. Seymour, Michael Dickinson, Eric Wong, Melita Kenealy, David Westerman, Kirsten Herbert
Publikováno v:
Leukemialymphoma. 54(4)
In a recent edition of this journal, Fianchi et al . [1] retrospectively analyzed the outcomes of 31 patients with chronic myelomonocytic leukemia (CMML) treated with the hypomethylating agent azacitidine. Th ere was variation in the dose schedule of
Autor:
Jih Tung Pai, Jin Hwang Liu, Jyh Pyng Gau, Ying Chung Hong, Cheng Hwai Tzeng, Han Nan Lin, Po Min Chen, Yuan Bin Yu, Liang Tsai Hsiao, Ching Fen Yang, Chunyu Liu, Tzeon Jye Chiou
Publikováno v:
Leukemialymphoma. 51(12)
Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma that carries a poor prognosis. This study retrospectively analyzed patients with AITL from a single institution in Taiwan, aiming to define the clinical feature
Autor:
Magdalini Migkou, Meletios A. Dimopoulos, Irini Grapsa, Despina Barmparousi, Maria Roussou, Evangelos Terpos, Charis Matsouka, Efstathios Kastritis, Erasmia Psimenou
Publikováno v:
Leukemialymphoma. 49(5)
Renal failure is a common feature of multiple myeloma and a major management problem. However there is limited data regarding the reversibility of renal failure, the kinetics of serum creatinine and the safety of novel agents such as bortezomib when
Autor:
Esa Jantunen, Irma Matinlauri, Tapio Nousiainen, Sari Hämäläinen, Taru Kuittinen, Irma Koivula
Publikováno v:
Leukemialymphoma. 49(3)
The objective of this study was to evaluate etiology and consequences of neutropenic fever in AML patients. Two hundred and ninety neutropenic periods following chemotherapy in 84 AML patients were retrospectively evaluated. Neutropenic fever was fou
Autor:
Serge Koscielny, E. Jabbour, J. H. Bourhis, P. Arnaud, J. M. Vantelon, Vincent Ribrag, Christophe Fermé, C. Bocaccio, N. Peslin, Patrice Carde
Publikováno v:
Leukemialymphoma. 46(6)
High-dose therapy (HDT) is now recommended for patients under 60 years of age with chemosensitive relapsed aggressive non-Hodgkin's lymphoma. However, approximately half of these patients will be cured by HDT. Prognostic factors are needed to predict